EIPICO is ushering in a new era by enriching the Egyptian pharmaceutical sector through the localization of biological and biosimilar product manufacturing at its groundbreaking facility, EIPICO 3. It marks a significant milestone as the first facility in Egypt and the Middle East to manufacture both drug substances and finished products.

EIPICO 3 has embraced the latest technology for manufacturing monoclonal antibodies (mAb) and other recombinant protein (small protein) products from cell lines, addressing one of the most pressing unmet medical needs (UMN) in the Egyptian market and aligning with the latest therapeutic trends worldwide. From day one, EIPICO made the strategic decision to adopt and implement the latest technology and adhere to cGMP (current Good Manufacturing Practice) guidelines for this project. This commitment aims to provide the Egyptian population with the highest quality medications at affordable prices compared to imported drugs.

EIPICO 3 is strategically located in the 10th of Ramadan City, in close proximity to EIPICO 2 facility. It boasts a built-up area of 12,750 square meters, utilizing prefabricated modular structure building techniques designed and fabricated by the Swedish company Pharmadule Morimatsu. The production area comprises 85 prefabricated modules with a built-up area of 4,777 square meters. Additionally, there are supportive buildings, including Packaging, Warehouse, Admin Building, QC (Quality Control), and Utilities, constructed with a concrete structure and a total built-up area of 8,000 square meters. The total CAPEX (Capital Expenditure) for this project amounts to approximately 100 USD.

The facility has been meticulously designed and constructed to meet the requirements of various manufacturing processes, including Up-Stream Process (USP), Down-Stream Process (DSP), Formulation, and Aseptic filling for finished products. It is fully equipped with the most recent manufacturing equipment, enabling the production of a wide range of targeted products while adhering to the process standards set by Reliance Life Science, a leading manufacturer in this field.

EIPICO 3's product portfolio includes approximately 14 products initially, covering various therapeutic areas.

Through the establishment of EIPICO 3, EIPICO is pioneering the localization of essential pharmaceutical products in Egypt, contributing to the country's healthcare landscape and advancing access to high-quality medicines for its people.